MultiValent Biotherapies
Los Altos, US · Founded 2025 · Delaware corporation
Founders & leadership
FM
Fred Max SchwarzerNamed on SEC filing
DR
Deborah Robbins SchwarzerNamed on SEC filing
SS
Stephen SnowdyNamed on SEC filing
BK
Bruce KeytNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$10M disclosed across 2 rounds · 2026
▶$10MraisedMar 2026 · 4 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fred SchwarzerExecutive Officer, Director, Promoter
- Stephen SnowdyExecutive Officer, Director, Promoter
- Bruce KeytExecutive Officer, Director, Promoter
- Deborah Robbins SchwarzerExecutive Officer, Director, Promoter
- Amount sold
- $10M
- Minimum investment
- $12.5K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
▶$4.4KraisedFeb 2026 · 11 investors · BiotechnologyRule 506(b)
▶$4.4KraisedFeb 2026 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fred Max SchwarzerExecutive Officer, Director, Promoter
- Deborah Robbins SchwarzerExecutive Officer, Director, Promoter
- Stephen SnowdyExecutive Officer, Director, Promoter
- Bruce KeytExecutive Officer, Director, Promoter
- Offering amount
- $4.4K
- Amount sold
- $4.4K
- Minimum investment
- $50
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has MultiValent Biotherapies raised?
- MultiValent Biotherapies has disclosed $10M raised across 2 rounds.
- Where is MultiValent Biotherapies headquartered?
- MultiValent Biotherapies is headquartered in Los Altos, US.